July 25, 2016 12:43 PM ET

Pharmaceuticals

Company Overview of Daiichi Sankyo, Inc.

Company Overview

Daiichi Sankyo, Inc. develops and markets pharmaceuticals. The company offers therapies in the areas of hypertension, dyslipidemia, diabetes, acute coronary syndrome, metastatic melanoma, cardiology, oncology, pain, and other aspects. It serves customers in the United States and internationally. Daiichi Sankyo, Inc. was formerly known as Sankyo Pharma Inc. and changed its name to Daiichi Sankyo, Inc. in April 2006. The company was founded in 1996 and is based in Parsippany, New Jersey. Daiichi Sankyo, Inc. operates as a subsidiary of Daiichi Sankyo Company, Limited.

Two Hilton Court

Suite 2

Parsippany, NJ 07054

United States

Founded in 1996

Phone:

973-359-2600

Fax:

973-359-2645

Key Executives for Daiichi Sankyo, Inc.

Executive Chairman, President, Global Head of Research & Development - Daiichi Sankyo Ltd and Senior Executive Officer - Daiichi Sankyo Ltd
Vice President of Operations
Chief Executive Officer of Daiichi Sankyo Co., Ltd. and President of Daiichi Sankyo Co., Ltd.
President of US Commercial
Age: 53
Executive Vice President and Head of Global Business Development
Compensation as of Fiscal Year 2016.

Daiichi Sankyo, Inc. Key Developments

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CL-108 for the relief of moderate to severe pain while preventing or reducing the associated opioid-induced nausea and vomiting (OINV). CL-108 is a fixed-dose, immediate-release bi-layered tablet with a rapid release layer containing 12.5 mg of promethazine and a second layer containing 7.5 mg of hydrocodone and 325 mg of acetaminophen. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 31, 2017.

Daiichi Sankyo, Inc. Presents at Sachs Associates 2nd Annual Immune-Oncology BD&L and Investment Forum, Jun-03-2016 11:00 AM

Daiichi Sankyo, Inc. Presents at Sachs Associates 2nd Annual Immune-Oncology BD&L and Investment Forum, Jun-03-2016 11:00 AM. Venue: Hyatt Chicago Magnificent Mile, 633 North Saint Clair Street, Chicago, IL 60611, United States. Speakers: Francis Kern, Senior Director, External Scientific Affairs.

Daiichi Sankyo, Inc. to Establish New U.S. Headquarters in Basking Ridge, New Jersey

Daiichi Sankyo, Inc. announced that it will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, NJ. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs. The new office will be located at 211 Mt. Airy Road, Basking Ridge, New Jersey.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Daiichi Sankyo, Inc., please visit dsi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.